The relation between erythropoietin, hematocrit and hemoglobin in breast cancer patients on non-nephrotoxic chemotherapy

European Journal of Gynaecological Oncology

Volumn 19, Issue 6, 1998, Pages 577-579

  Shamseddine, A ^a   Khalil, A ^a   Seoud, M ^a   Kahwaji, S ^a   Taher, A ^a   Bizri, A R ^a   Medawar, W ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Anemia; Breast cancer; Chemotherapy; Erythropoietin

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROPOIETIN; FLUOROURACIL; HEMOGLOBIN; METHOTREXATE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOCRIT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADENOCARCINOMA; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN; FEMALE; FLUOROURACIL; HEMATOCRIT; HEMOGLOBINS; HUMANS; METHOTREXATE; NEOPLASM STAGING; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 0032444315     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Krantz S. B.: "Erythropoietin". Blood, 1991, 77, 419.
2. Semenga G. L.: "Regulation of Erythropoietin production". Hematol. Oncol. Clinic. North. Am., 1994, 8 (5), 863.
3. Alexandre W. J., George W. Y., Eisela C. K., Joseph G. F., Walter N. E.: "Erythropoietin-hematocrit feedback circuit in the anemia of end stage renal disease". Kidney Int., 1987, 31, 1205.
4. Moliterno A. R., Spivak J. L.: "Anemia of cancer". Hematol. Oncol. North. Am., 1996, 10 (2), 345.
5. Miller C. B., Jones R. J., Piantadosi S., Abeloff M. D., Spivak J. L.: "Decreased erythropoietin response in patients with the anemia of cancer". N. Engl. J. Med., 1990; 322, 1689.
6. Schapira L., Antin J. H., Ransil B. J., Antman K. H., Eder J. P., McGarigle C. J. et al.: "Serum erythropoietin level in patients receiving intensive chemotherapy and radiotherapy". Blood, 1990, 76, 2354.
7. Takeicki N., Umemura T., Nishimura J., Motomura S., Kozuru M., Ibaya S.: "Regulation of erythropoietin and burst. Promoting activity production in patients with aplastic anemia and iron deficiency anemia". Acta Hematol., 1988, 80, 145.
8. Deklerk G., Rosengarter P. C. J., Vet R. J. W. M., Goudsmit R.: "Serum erythropoietin titers in anemia". Blood, 1981, 58, 1164.
9. Birgegard G., Wide L., Simonsson B.: "Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanisms other than anaemia for stimulation". Br. J. Haematol., 1989, 72, 462.
10. Piroso E., Ersler A., Aro J.: "Inappropriate increase in erythropoietin titers during chemotherapy". Am. J. Hematol., 1989, 32, 248.
11. Hasegawa I., Tanaka K.: "Serum erythropoietin levels in gynecologic cancer patients during cisplatin combination chemotherapy". Gynecol. Oncol., 1992, 46, 65.
12. Miller C. B., Jones R. J., Zahurak M. L., Piantadosi S., Burns W. H., Santos G. W. et al/: "Impaired erythropoietin response to anemia after bone marrow transplantation". Blood, 1992, 80, 2677.
13. Esler A. J.: "Erythropoietin". N. Engl. J. Med., 1992, 42, 1339.
14. Prasad V. K., Kendall R. G., Bailey C. C., Hale J.: "The relationship between serum erythropoietin (EPO) and blood hemoglobin (Hb) in children receiving nephrotoxic chemotherapy agents". Blood, 1996, 88, No. 10, (Suppl. 1), 140b (Abstr. #3289).
15. Cazzola M., Guarnone R., Beguin Y.: "Red cell precursor mass as an independent determinant of serum erythropoietin level". Blood, 1996, 88, No. 10, (Suppl. 1), 3480 (Abstr. #1381).